Drugs / Group B streptococcus vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01412801 | Sep 2011 → Oct 2012 | streptococcal infection | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Group B streptococcus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01412801 ↗ |
| Modality | Vaccine | “received a 5 μg dose of glycoconjugate GBS vaccine (serotypes Ia, Ib, and III, with CRM197 [Novartis Vaccines, Siena, Italy]) intramuscularly at 24-35 weeks' gestation.” PMID 26869376 ↗ Feb 2016 |
| Route | Intramuscular | “intramuscularly at 24-35 weeks' gestation” PMID 26869376 ↗ Feb 2016 |